Michael S. Weiss - 08 Jan 2026 Form 4 Insider Report for TG THERAPEUTICS, INC. (TGTX)

Role: CEO, Director
Signature: /s/ Michael S. Weiss
Issuer symbol: TGTX
Transactions as of: 08 Jan 2026
Net transactions value: $0
Form type: 4
Filing time: 09 Jan 2026, 17:16:39 UTC
Previous filing: 07 Nov 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
WEISS MICHAEL S	CEO, Director	3020 CARRINGTON MILL BLVD, SUITE 475, MORRISVILLE	/s/ Michael S. Weiss	09 Jan 2026	0001038977

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TGTX	Common Stock	Award	$0	+622,000	+6.8%	$0.000000	9,778,086	08 Jan 2026	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Reflects a grant of restricted shares, all of which will vest on the first anniversary of the date on which the first of any of the following occur: (i) the Company's total shareholder return (TSR) exceeds the TSR of the Nasdaq Biotechnology Index (NBI) over a 3-year period; (ii) the Company's TSR exceeds the TSR of the NBI over a 5-year period; (iii) the Company's TSR exceeds the TSR of the NBI over a 7-year period; or (iv) the Company's TSR exceeds the TSR of the NBI over a 9-year period.
F2	Includes shares of restricted Common Stock, which vest over various time periods.

Content

Reflects a grant of restricted shares, all of which will vest on the first anniversary of the date on which the first of any of the following occur: (i) the Company's total shareholder return (TSR) exceeds the TSR of the Nasdaq Biotechnology Index (NBI) over a 3-year period; (ii) the Company's TSR exceeds the TSR of the NBI over a 5-year period; (iii) the Company's TSR exceeds the TSR of the NBI over a 7-year period; or (iv) the Company's TSR exceeds the TSR of the NBI over a 9-year period.

Includes shares of restricted Common Stock, which vest over various time periods.